It was a research project done by a grad student - no way he/she was capable of doing many more than 14 patients or so, and costly for AMRN to support a larger one. I got my M.S. (for free) working as an RA on a $500k contract funded by the USAF/NASA that my professor had snagged to do some research, which was the basis for my thesis. That money was all dedicated to my project alone - equipment costs, lab costs, admin support, my tuition, my stipend, etc. - that ain't small change for AMRN's current financial position, assuming they paid the university a similar amount of money.
But yeah, would sure love to see more of these L vs. V studies, real eye openers for docs currently prescribing generic L instead of V to their patients!
Ooo! Ooo! Just had another thought - there is nothing preventing AMRN and Kowa reps from distributing this research paper to docs! It makes no claims about reducing CVE, just shows V is better than L - this could give a big boost to our sales! And a poke in the eye to the FDA ;-)
News 
Market Data 
Discover 
